12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
The outbreak of the novel coronavirus COVID-19 is posing a major challenge to cross-border transacti...
Read More >
Earlier this week, on Monday, we had reported that New Jersey was allowing, subject to proper distan...
Read More >
On Thursday, January 30, members from Verrill's Employment & Labor group, as well as some from the E...
Read More >
On April 8, 2020, Governor Murphy signed Executive Order No. 122 (the Order) strengthening mitigatio...
Read More >
Some interesting links we found across the web this week: How Some Founders are Raising Capital Out...
Read More >
Independent Contractor Agreements Should be Reviewed - With Assembly Bill 5 taking effect Jan. 1, p...
Read More >